INTRODUCTION
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase that exists in two highly homologous forms: GSK-3α and GSK-3β encoded by two different genes [1] [2] [3] . Moreover, in humans, a splice variant (GSK-3β2) has been reported 4 . The role of GSK-3 as a drug target has been implicated in a variety of unmet human diseases, such as Alzheimer's disease (AD) [5] [6] [7] [8] , bipolar disorder 9, 10 , various forms of cancers 11, 12 , diabetes 13 , and many other diseases [14] [15] [16] [17] .
Over the past years "harder targets" that belong to large super-families like kinases have been addressed in drug discovery. Drug modulators that target the kinase catalytic domain risk serious off-target effects 18 . Moreover, it is still challenging to identify other well defined druggable sites on kinases. Kinetic experiments can depict the mode of inhibition but fail to predict the binding locations on the protein; however, pocket detection algorithms can predict likely binding locations of both orthosteric and allosteric pockets. In this research, the GSK-3β binding sites were assessed with a druggability assessment tool (SiteMap) 19 from Schrödinger, Inc. SiteMap is an energy-based pocket detection algorithm that finds, visualizes, and evaluates protein binding sites. Energy-based methods identify binding sites by docking small organic probes, typically methane or water molecules, on a given target protein to evaluate whether a given protein region interacts favorably 20 . SiteMap is computationally more demanding as this tool provides insights into the physical basis of druggability classification of the target protein sites with high predictive ability.
The X-ray crystal structures reveal three well-known binding sites of GSK-3β: (i) the ATP site, (ii) the substrate binding site, and (iii) the Axin/Fratide binding site. In addition, four allosteric pockets on GSK-3β were recently reported (pockets 
4-7)
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. Our recent program identified an additional small allosteric pocket at the C-lobe of GSK-3β (pocket 8). Structurally, GSK-3 is a two-domain kinase fold comprising a β-strand domain and an α-helix domain. The residues forming the ATP-binding site (pocket 1) are seated deep between the interface of the α-helix and β-strand domains surrounded by a hinge region and a glycine-rich loop, which is often referred to as "P-loop" [22] [23] [24] [25] . The substrate binding site (pocket 2) is surrounded by the C-loop and the activation loop. Both pockets are sandwiched between the interfaces of the N-and C-lobes of GSK-3β. The third known pocket is the Axin/Fratide binding site (pocket 3). Pockets 4-8 are the allosteric sites of the kinase shown in Figure 1 .
METHODOLOGY
All computational and molecular modeling studies were carried out using Schrödinger molecular modeling software, version 9.3.5 on a windows Dell workstation.
Protein preparation
Twenty-four different X-ray crystal structures of human GSK-3β were extracted from the Protein Data Bank (PDB) by maintaining selection criteria close to 2.5 angstroms. GSK-3β is crystallized as a homodimer comprising of chains A and B. In a few cases of the crystallographic structures, chain A monomers were crystallized with Axin and Fratide peptides, and in some cases they exist as a homodimer or monomer protein. The dimer structures within each PDB case were separated to retain the chain A monomers as in many cases, site search may generate unphysical sites over the entire dimer structures. Each individual chain A monomers were preprocessed with the Protein Preparation Wizard in the Maestro program, with the following default options selected: "assign bond orders," "add hydrogen atoms," "create zero-order bonds to metals," "create disulphide bonds," and "delete water molecules beyond 5Å from heteroatom groups." The optimal protonation states of each ionizable residue were assigned and the hydrogen-bonding network was optimized for proteins with structural ambiguity. A restrained minimization with an OPLS2005 force field was performed to attain the relaxed state of each refined complex.
Site identification
SiteMap identifies a site as an enclosed region on the protein surface comprising at least 15 site points (default settings) 26 . To locate a site the search uses a grid of points called "site points." Following the default protocol in SiteMap v2.6, a more restrictive definition of hydrophobicity, a standard grid, and the OPLS2005 force field were used.
The refined chain A monomers were then submitted to SiteMap for druggability assessment. To avoid a biased search, all crystallographic water molecules, ligands, metal ions, heteroatom groups, unwanted chains, and peptides were removed prior to the site search. SiteMap was assigned to report up to 10 sites to avoid ambiguity that matches with the known sites of GSK-3β (default settings: 5).
Druggability assessment by SiteMap
The druggability of a protein binding pocket is calculated by various physical descriptors in SiteMap, which were calibrated for submicromolar tight-binding sites Where, n = number of site points (capped at 100) e = enclosure score, and p = hydrophilic score (capped at 1.0).
For SiteScore the hydrophilic score is capped at 1.0 whereas the hydrophilic score is uncapped in Dscore to penalize highly polar sites. This critical feature in Dscore classifies binding sites between "druggable," "difficult," and "undruggable" sites on a protein.
RESULTS AND DISCUSSION
A dataset of twenty-four different X-ray crystal structures of GSK-3β was prepared and submitted to SiteMap for druggability assessment, as described in the methods section. We denote an average of eight surface pockets found on the structure of GSK-3β. Among them, three pockets (1, 4 and 7) were consistently retrieved in all crystal structures analyzed by SiteMap.
Classifying ligand-binding sites of GSK-3β
We first analyzed the SiteScore data to identify plausible ligand-binding sites. Based on the previously recommended cut-off scores, SiteScore can be applied as a classifier to predict ligand-binding sites (SiteScore ≥ 0.80) or non-ligandbinding sites (SiteScore < 0.80) and a score higher than 1.01 indicate highly potential binding sites 26 .
Pockets 1 and 7 demonstrate SiteScores higher than 0.80 with promising ligand-binding capabilities, as shown in Table 1 . Interestingly, for site 7 the PDB entry 1I09 and 4NM0 reveal two separate pockets very close in space surrounded by the same region. In these cases, the observed low scores were correlated with the small volume of each pocket. In several cases across our dataset, six pockets (2, 3, 4, 5, 6, and 8) have median SiteScores less than the cut-off range.
Classifying druggable binding sites of GSK-3β
In addition to SiteScore, we also analyzed the druggability of each site of GSK-3β (Table 2) . Considering the Dscore criteria, binding sites of a protein can be classified into "druggable," "undruggable," and "medium druggable/difficult" sites 26 .
Druggable site (Dscore > 0.98)
A typical druggable site is recognized by its good size, deeply buried pocket and often hydrophobic character. Among the eight sites identified, pocket 1 was the largest predicted site with a median Dscore higher than 0.98 (83% cases). Moreover, undruggable sites (Dscore < 0.83) were not identified in any cases for pocket 1, indicating a druggable pocket of GSK-3β (Table 2 ). All other pockets, in most cases, fail the druggability criteria.
Difficult sites (Dscore between 0.83 and 0.98)
SiteMap druggability scores recognize pocket 7 as a "difficult" site with the highest predicted cases scoring between 0.83 and 0.98. In addition, in few cases pocket 1 (16%), pocket 2 (5%), pocket 3 (18%), and pocket 4 (13%) scored in the intermediate range. Despite the adequate size and volume of the site, with exceptional hydrophilicity, an important reason to classify site 7 as an "intermediate site" is the low hydrophobic nature of the site (quantitative median phobic score is approximately 0.3) ( Table 3) . To facilitate comparison, we visualized the surface maps of a "druggable" site (pocket 1) and a "difficult" site (pocket 7) identified by SiteMap (Figure 2 and 3) . A clear difference is observed for pocket 7, which lacks sufficient sized hydrophobic regions (yellow maps). The hydrogenbond donor and acceptor regions of this pocket (blue and red maps, respectively) are scattered over the entire cavity while these regions are more concentrated surrounding the entire hydrophobic region of pocket 1.
Furthermore, we explored the quantitative pocket characteristics of site 7, as summarized in Table 3 . This site is relatively open to solvent with moderately high average exposure scores of 0.69 (calibrated score: ~0.49). Moreover, the site is partially buried with an average enclosure score of 0.64 (calibrated score: ~0.78; higher scores are considered better for a deeply buried pocket). The degree of contact measures the relative tightness between a ligand and the binding site. Here, the contact property displayed relatively lower scores, observed to be 0.8 compared to the standard values (calibrated score: ~1). As a result, it would be more challenging to design high affinity drug-like molecules for this site. Moreover, the donor/acceptor character of this pocket quantifies moderate hydrogen-bond possibilities between a well-structured ligand and the site. These features represent the overall characteristics of a "difficult" pocket assessed by SiteMap. The undruggable sites are shallow protein surface pockets, extremely hydrophilic with negligible hydrophobic nature, characterized by Dscores below 0.80. The druggability scores recognize pockets 5, 6, and 8 as undruggable sites (100% cases). Several cases for pocket 2 (95%) and pocket 4 (87%) were also categorized as undruggable sites (Table 2) . SiteMap identified pocket 3 as having two or three distinct cavities within the same binding region, annotated with their respective scores shown in Tables 1 and 2 . This yielded a total of 33 sites, of which 27 sites exhibited median Dscores, less than 0.83 (82% undruggable cases). Phobic and philic terms are the hydrophobic and hydrophilic scores, respectively.
Computational Validation of Generated Pockets
The pockets identified by SiteMap analysis were validated with the known cocrystal structures available at the time of the study. Seven different cavities are supported by X-ray crystallographic studies in the Protein Data Bank (PDB) where ligands (pocket 1), peptides (pocket 2 and 3) and even heteroatoms (pocket 4, 5, 7, and 8) are known to be captured within these cavities, while pocket 6
represents an orphan site.
Pocket 1:
A variety of heterocyclic ligands are known to mimic the GSK-3β active site. To validate this site, the PDB structure of 1Q4L was selected which has an anilino-maleimide crystallized within GSK-3β 27 . Quesada-Romero et al. reported the orientation of several maleimide derivatives that adopt the GSK-3β active site 28 . Figure 2 has been taken from the same perspective to confirm the druggability and binding of such ligands to this pocket. A maleimide core structure attached to two aryl rings occupies the yellow hydrophobic region. The carboxylate group and one of the acyl groups of the ligand lie in the red acceptor region, while the NH group of the core maleimide structure occupies the blue donor region. The anilino group just failed to spot the donor region. Here, SiteMap accuracy is judged as the distance between the anilino group and the carbonyl oxygen atom of Val135 is 3.63 Å, which is quiet far for a strong hydrogen-bond interaction.
Pocket 2:
This pocket is recognized as the substrate binding site. A pS9 autoinhibitory peptide 29 recognizing the substrate site is shown in figure 4 . Key hydrogen-bond interactions are recognized with the primed phosphate groups of the peptide and a triad of three basic residues (Arg96, Arg180, and Lys205). Furthermore, the backbone of the peptide is shown to interact with the Lys94 residue of this site. These interactions confirm the binding of such peptides in this pocket.
Figure 4.
A pS9 auto-inhibitory peptide is shown to interact with the substrate site of GSK-3β in the 4NU1 structure together with a 2D structure representation.
Pocket 3:
The Axin and Fratide peptides recognize the peptide-binding channel comprising α-helix (residues 262-273) and the extended loop (residues 285-299) at the C-lobe of GSK-3β [30] [31] [32] . In several cases across our dataset, two to three small cavities were observed within the entire channel. Among these, a distinct "hydrophobic patch" identified by SiteMap formed with the hydrophobic residues of the α-helix, and the extended loop provides favorable peptidebinding characteristics ( Figure 5 ). 
Pocket 5:
A shallow pocket is located at the N-lobe of GSK-3β. In the PDB structure of 4NU1, a molecule of glycerol is shown to bind in this pocket. The polar and charged residues (Tyr56, Lys86, and Asn129) surrounding the small cavity are significant enough to form hydrogen-bond contacts with small hydrophilic glycerol molecules, as shown in Figure 8 . 
Pocket 6:
The major residues lining a small cavity in the hinge domain were identified as pocket 6 ( Figure 9) . No ligands or heteroatoms are known to bind in this pocket, which represents an orphan site. Figure 9 . The total surface of pocket 6 represented as gray and the site points as white spheres (PDB ID: 1O9U, blue cartoon representation).
Pocket 7:
SiteMap scores recognize pocket 7 as the most promising allosteric site of GSK-3β. In the crystallization experiments, a few heteroatom and reagent molecules are known to be captured in this pocket. To support our result, the PDB structure of 4NM0 was selected, which has Dithiothreitol (DTT) molecule crystallized within GSK-3β 29 . Key hydrogen-bond interaction is recognized between the DTT molecule and residues Thr326, Ala327, and Arg319 of pocket 7, as shown in Figure 10 . In addition, the binding residues Arg209 and His173 of the same pocket in the PDB structures of 1UV5, 1I09, and 1GNG also chelates phosphate and sulfate ions present in the crystallization experiments. These interactions are crucial for understanding the important residues for allosteric modulation of the kinase.
Pocket 8:
A new small pocket identified by SiteMap is located at the C-lobe of GSK-3β. The presence of glycerol with a hydrogen-bond to Val155 is observed in the PDB structures of 3ZRM (Figure 11 ). The presence of such hydrophilic molecules can provide clues for the prevalence of these pockets on GSK-3β. 
CONCLUSIONS
Predicted druggability on the pockets of GSK-3β were assessed by SiteMap. With the aim to identify druggable sites of GSK-3β, SiteMap studies yielded useful insights that clearly distinguish druggable, difficult, and undruggable sites. These results conclude that the ATP-binding site is the only druggable pocket of GSK-3β, while pocket 7 is a "difficult" pocket, as analyzed by SiteMap. Although this pocket is classified as a "difficult site" by SiteMap analysis, it has earmarks as a good binding site and the possibility of designing selective allosteric modulators. With the help of SiteScore we successfully differentiated the ligand and non-ligand-binding sites of GSK-3β; however, the identification of non-ligandbinding sites or difficult/undruggable sites does not mean that a ligand cannot bind to such sites. Moreover, it would be challenging to search such drug-like ligands that bind with high affinity on these sites. At the moment, SiteMap studies have classified the pockets of GSK-3β based on the druggability score, which can clearly classify these sites between druggable, difficult, and undruggable sites. We predict that these results will add to the accuracy in identifying druggable pockets of GSK-3β.
